DYNAMIKA™ delivers SOC 2 Type II–certified, AI‑driven imaging workflows, giving pharma and biotech secure, compliant ...

Whole-blood transfusion has recently gained favor in the management of severe hemorrhage; however, data from large clinical trials evaluating its clinical effectiveness and safety are lacking. We ...

In a new pharmaphorum podcast, web editor Nicole Raleigh was joined by Rob DiCicco, vice president of portfolio management at ...

Q4 2025 earnings call: 2026 revenue guidance $52–$56M, IRRAS integration, FDA updates, and growth outlook—read key takeaways.

Biotech picks highlight cystic fibrosis drug trials, rare-disease therapies and upcoming regulatory catalysts as clinical data and approvals approach.

On track for third quarter 2026 top-line trial results from anticipated pivotal Phase 2b clinical trial (ELPIS II) evaluating laromestrocel as a potential adjunct treatment for HLHS, a rare pediatric ...

Opioids only provide small, short-lasting relief or are ineffective for many acute pain conditions, an overview of systematic ...

Zong has announced the results of its latest 5G speed tests in Islamabad, with peak download speeds exceeding 1.4 Gbps. The pre-launch trials were ...

Healthcare provider, LivingCare Group has been selected as the proposed imaging partner for the IMProVE clinical trial, a prostate cancer early-detection programme funded by Yorkshire Cancer Research.

Survival in myeloma is clearly being prolonged,” says Mikhael. “Whereas historically, we saw a greater impact in younger ...

Alchemab Therapeutics has appointed Ulrich Wendt as Chief Business Officer to expand partnerships with biopharma for novel antibody therapeutics.

Polyrizon Ltd. (Nasdaq: PLRZ) ("Polyrizon" or the "Company"), a pre-clinical-stage biotechnology company developing intranasal administrated solutions ...